On Friday, 22 January 2021, Knowledge Ecology International delivered the following remarks on WHO”s Global Observatory on Health R&D at the 148th session of WHO’s Executive Board. At meetings of WHO governing bodies, non-State actors are limited to one minute… Continue Reading
General Statement of Knowledge Ecology International – Sixty-First Series of Meetings of the Assemblies of the Member States of WIPO (WIPO Assemblies) Agenda item 5 – General Statements 21 September 2020 In relation to the COVID-19 response, Knowledge Ecology International… Continue Reading
KEI Research Note: 2020-4: The current and potential role of biomedical research mandates 2020 The current and potential role of biomedical research mandates. Progress in biomedical research depends upon funding. This funding comes from a variety of public sector, non-profit… Continue Reading
Below is a link to an essay on the use of the phrase “global public goods”. The essay focuses on the three papers Paul Samuelson wrote in the 1950s that are often used, and misused, to define public goods. Samuelson’s… Continue Reading
KEI is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the 73rd World Health Assembly. https://extranet.who.int/nonstateactorsstatements/meetingoutline/6 Knowledge Ecology International Meeting: Seventy-third World Health Assembly Written statements on COVID-19 pandemic The biggest question today… Continue Reading
The World Intellectual Property Organization (WIPO) is convening an extraordinary session of the WIPO General Assembly from May 7, 2020 to May 8, 2020; the purpose of this extraordinary session of the General Assembly is to appoint Mr. Daren Tang… Continue Reading
KEI filed these comments on the NIH Draft Policy for Data Management and Sharing and Supplemental DRAFT Guidance January 10, 2019 1621 Connecticut Avenue NW Suite 500 Washington, DC 20009 www.keionline.org January 10, 2020 Office of Science Policy National Institutes… Continue Reading
On Friday, 18 October 2019, South Africa delivered the following statement at the WTO TRIPS Council on transparency of R&D Costs and Pricing of Medicines and Health Technology. Intellectual Property and the Public Interest: R&D Costs and Pricing of Medicines… Continue Reading
On October 11, 2019, the U.S. Congressional Budget Office (CBO) sent a letter to Representative Frank Pallone Jr., Chairman of the Committee on Energy and Commerce, describing a preliminary estimate of the effects of Title I of H.R. 3 bill.… Continue Reading
One of the reasons why drug companies have fought so hard to block transparency of clinical trial costs is the growing gap between what the public had been told those costs are, and the actual costs, particularly for treatments for… Continue Reading